Browsing by Author "Kiraz, Sedat"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
Publication Are there any clues to predict bamboo spine in axial spondyloarthritis?(Wiley, 2020-10-01) Atagündüz, Pamir; Kiraz, Sedat; Akar, Servet; Küçükşahin, Orhan; Erden, Abdulsamet; Beş, Cemal; Kılıç, Levent; Karadağ, Ömer; Kaşifoğlu, Timuçin; Emmüngil, Hakan; Çınar, Muhammet; Kimyon, Gezmis; Yazısız, Veli; Ateş, Aşkın; Ersözlü, Emine Duygu; Gonullu, Emel; Mercan, Rıdvan; Ertenli, İhsan; Kalyoncu, Umut; Yağız, Burcu; YAĞIZ, BURCU; Coşkun, Nihan; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CLH-7318-2022Item The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey(Clinical & Exper Rheumatology, 2012) Malhan, Simten; Pay, Salih; Ataman, Şebnem; Dinç, Ayhan; Erken, Eren; Ertenli, İhsan; Ertuǧrul, Esin; Göǧüş, Feride Nur; Hamuryudan, Vedat; İnanç, Murat; Karaaslan, Yaşar; Karadağ, Ömer; Karakoç, Yüksel; Keskin, Göksal; Kısacık, Bünyamin; Kiraz, Sedat; Oksel, Fahrettin; Öksüz, Ergün; Pırıldar, Timur; Sarı, İsmail; Soy, Mehmet; Şentürk, Taşkın; Taylan, Ali; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi.; 6506739457Objectives: To determine the direct and indirect costs due to rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients in Turkey. Methods: An expert panel was convened to estimate the direct and indirect costs of care of patients with RA and AS in Turkey. The panel was composed of 22 experts chosen from all national tertiary care rheumatology units (n=53). To calculate direct costs, the medical management of RA and AS patients was estimated using "cost-of-illness" methodology. To measure indirect costs, the number of days of sick leave, the extent of disability, and the levels of early retirement and early death were also evaluated. Lost productivity costs were calculated using the "human capital approach", based on the minimum wage. Results: The total annual direct costs were 2,917.03 Euros per RA patient and 3,565.9 Euros for each AS patient. The direct costs were thus substantial, but the indirect costs were much higher because of extensive morbidity and mortality rates. The total annual indirect costs were 7,058.99 Euros per RA patient and 6,989.81 for each AS patient. Thus, the total cost for each RA patient was 9,976.01 Euros and that for an AS patient 10,555.72 Euros, in Turkey. Conclusion: From the societal perspective, both RA and AS have become burden in Turkey. The cost of lost productivity is higher than the medical cost. Another important conclusion is that indirect costs constitute 70% and 66% of total costs in patients with RA and AS, respectively.Publication Factors that may be associated with uveitis in patients with spondyloarthritis(Wiley, 2018-09-01) Kaşifoğlu, Timuçin; Bilge, Nazife Şule Yaşar; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıc, Ediz; Bes, Cemal; Kanitez, Nilüfer Alpay; Atagündüz, Pamir; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çinar, Muhammed; Ateş, Aşkın; Akar, Servet; Gercik, Onay; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Kimyon, Gezmiş; Tufan, Müge Aydın; Emmungil, Hakan; Mercan, Rıdvan; Bodakçı, Erdal; Öz, Burak; Akar, Zeynel Abidin; Karadağ, Ömer; Keleşoğlu, Bahar; Yılmaz, Sedat; İlgen, Ufuk; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bölümü; CMF-4757-2022Publication Identification of susceptibility loci for takayasu arteritis through a large multi-ancestral genome-wide association study(Cell Press, 2021-01-07) Ortiz-Fernandez, Lourdes; Saruhan-Direskeneli, Guher; Alibaz-Oner, Fatma; Kaymaz-Tahra, Sema; Coit, Patrick; Kong, Xiufang; Kiprianos, Allan P.; Maughan, Robert T.; Aydin, Sibel Z.; Aksu, Kenan; Keser, Gokhan; Kamali, Sevil; Inanc, Murat; Springer, Jason; Akar, Servet; Onen, Fatos; Akkoc, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadag, Omer; Kiraz, Sedat; Forbess, Lindsy; Langford, Carol A.; McAlear, Carol A.; Ozbalkan, Zeynep; Yavuz, Sule; Cetin, Gozde Yildirim; Alpay-Kanitez, Nilufer; Chung, Sharon; Ates, Askin; Karaaslan, Yasar; McKinnon-Maksimowicz, Kathleen; Monach, Paul A.; Ozer, Huseyin T. E.; Seyahi, Emire; Fresko, Izzet; Cefle, Ayse; Seo, Philip; Warrington, Kenneth J.; Ozturk, Mehmet A.; Ytterberg, Steven R.; Cobankara, Veli; Onat, Ahmet Mesut; Duzgun, Nursen; Bicakcigil, Muge; Yentur, Sibel P.; Lally, Lindsay; Manfredi, Angelo A.; Baldissera, Elena; Erken, Eren; Yazici, Ayten; Kisacik, Bunyamin; Kasifoglu, Timucin; Dalkilic, Ediz; Cuthbertson, David; Pagnoux, Christian; Sreih, Antoine; Reales, Guillermo; Wallace, Chris; Wren, Jonathan D.; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Sun, Ying; Chen, Huiyong; Grayson, Peter C.; Tombetti, Enrico; Jiang, Lindi; Mason, Justin C.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; 0000-0002-0247-4280; 0000-0003-0660-764X; 0000-0003-4153-903X; 0000-0001-7289-1816; 0000-0002-6376-5583; 0000-0002-3734-1242; 0000-0002-6341-2622; 0000-0002-3718-171X; 0000-0002-8270-2617; 0000-0003-1372-1555; 0000-0003-1185-5816; 0000-0003-4937-0515; 0000-0001-8764-4543; 0000-0003-4965-2918; 0000-0002-8914-9690; 0000-0001-7708-2487; 0000-0002-4530-7167; 0000-0002-7054-1203; 0000-0003-2167-4509; 0000-0002-3785-9834; 0000-0001-6287-9549; 0000-0002-7864-0185; 0000-0001-9993-3916; 0000-0001-9755-1703; 0000-0003-2776-3545; 0000-0003-1123-1464; 0000-0002-7122-9713; 0000-0001-7783-1660; 0000-0001-9284-7345; 0000-0003-2598-5806; GPP-1272-2022; CAG-1626-2022; ISU-1002-2023; D-2668-2012; AAA-6647-2020; AAT-3653-2020; HLH-8218-2023; AAT-3636-2020; KLZ-4006-2024; W-7332-2019; D-9870-2011; GOJ-7451-2022; C-4612-2015; KHW-8303-2024; AAD-5448-2019; AAA-8970-2021; P-4517-2015; L-1241-2015; HJI-6996-2023; JFJ-3399-2023; AAB-3576-2020; C-7018-2014; K-5378-2018Takayasu arteritis is a rare inflammatory disease of large arteries. We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 affected individuals) from five different populations. We discovered HLA risk factors and four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chr13q21 and reinforced IL12B, PTK2B, and chr21q22 as robust susceptibility loci shared across ancestries. Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a potential causal gene for chr21q22 association. We also identified >60 candidate loci with suggestive association (p < 5 x 10(-s)) and devised a genetic risk score for Takayasu arteritis. Takayasu arteritis was compared to hundreds of other traits, revealing the closest genetic relatedness to inflammatory bowel disease. Epigenetic patterns within risk loci suggest roles for monocytes and B cells in Takayasu arteritis. This work enhances understanding of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new therapeutic targets.Publication Leflunomide as a concomitant dmard choice for the biological treatment era of rheumatoid arthritis(Wiley, 2018-09-01) Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Beş, Cemal; Kanitez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Emmungil, Hakan; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Askin; Akar, Servet; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Tufan, Müge Aydın; Mercan, Rıdvan; Karadağ, Ömer; Keleşoğlu, Ayşe Bahar; Gercik, Onay; Öz, Burak; Akar, Zeynel Abidin; Yılmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Tekgöz, Emre; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022Publication Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic(TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.